These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 2959438)
21. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet; 1998 Sep; 352(9131):854-65. PubMed ID: 9742977 [TBL] [Abstract][Full Text] [Related]
22. Beneficial effect of lixisenatide after 76 weeks of treatment in patients with type 2 diabetes mellitus: A meta-analysis from the GetGoal programme. Broglio F; Mannucci E; Napoli R; Nicolucci A; Purrello F; Nikonova E; Stager W; Trevisan R Diabetes Obes Metab; 2017 Feb; 19(2):248-256. PubMed ID: 27762096 [TBL] [Abstract][Full Text] [Related]
23. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Yki-Järvinen H; Kauppinen-Mäkelin R; Tiikkainen M; Vähätalo M; Virtamo H; Nikkilä K; Tulokas T; Hulme S; Hardy K; McNulty S; Hänninen J; Levänen H; Lahdenperä S; Lehtonen R; Ryysy L Diabetologia; 2006 Mar; 49(3):442-51. PubMed ID: 16456680 [TBL] [Abstract][Full Text] [Related]
24. Energy metabolism and substrates oxidative patterns in type 2 diabetic patients treated with sulphonylurea alone or in combination with metformin. Avignon A; Lapinski H; Rabasa-Lhoret R; Caubel C; Boniface H; Monnier L Diabetes Obes Metab; 2000 Aug; 2(4):229-35. PubMed ID: 11225656 [TBL] [Abstract][Full Text] [Related]
25. Acarbose vs. bedtime NPH insulin in the treatment of secondary failures to sulphonylurea-metformin therapy in type 2 diabetes mellitus. López-Alvarenga JC; Aguilar-Salinas CA; Velasco-Perez ML; Arita-Melzer O; Guillen LE; Wong B; Brito G; Mercado V; Gómez-Pérez FJ; Rull-Rodrigo JA Diabetes Obes Metab; 1999 Jan; 1(1):29-35. PubMed ID: 11221809 [TBL] [Abstract][Full Text] [Related]
26. Type II diabetic subjects with secondary failure: treatment with prebreakfast mixed ultralente and regular insulin with a sulfonylurea. Kabadi UM; Kabadi MU J Fam Pract; 1991 Oct; 33(4):349-53. PubMed ID: 1919450 [TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea. Lukashevich V; Del Prato S; Araga M; Kothny W Diabetes Obes Metab; 2014 May; 16(5):403-9. PubMed ID: 24199686 [TBL] [Abstract][Full Text] [Related]
28. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study. Gerstein HC; Yale JF; Harris SB; Issa M; Stewart JA; Dempsey E Diabet Med; 2006 Jul; 23(7):736-42. PubMed ID: 16842477 [TBL] [Abstract][Full Text] [Related]
29. Glycaemic control and adverse events in patients with type 2 diabetes treated with metformin + sulphonylurea: a meta-analysis. Belsey J; Krishnarajah G Diabetes Obes Metab; 2008 Jun; 10 Suppl 1():1-7. PubMed ID: 18435668 [TBL] [Abstract][Full Text] [Related]
30. Recognition of fasting or overall hyperglycaemia when starting insulin treatment in patients with type 2 diabetes in general practice. Vähätalo M; Rönnemaa T; Viikari J Scand J Prim Health Care; 2007 Sep; 25(3):147-53. PubMed ID: 17846932 [TBL] [Abstract][Full Text] [Related]
31. Efficacy of combined treatments in NIDDM patients with secondary failure to sulphonylureas. Is it predictable? Trischitta V; Italia S; Raimondo M; Guardabasso V; Licciardello C; Runello F; Mazzarino S; Sangiorgi L; Anello M; Vigneri R J Endocrinol Invest; 1998 Dec; 21(11):744-7. PubMed ID: 9972673 [TBL] [Abstract][Full Text] [Related]
32. Long-term glycaemic control with metformin-sulphonylurea-pioglitazone triple therapy in PROactive (PROactive 17). Scheen AJ; Tan MH; Betteridge DJ; Birkeland K; Schmitz O; Charbonnel B; Diabet Med; 2009 Oct; 26(10):1033-9. PubMed ID: 19900236 [TBL] [Abstract][Full Text] [Related]
33. The effect of short term intensive insulin therapy in non-insulin-dependent diabetics who had failed on sulphonylurea therapy. Samanta A; Burden AC; Jones GR; Clarkson L Diabetes Res; 1986 Jun; 3(5):269-71. PubMed ID: 3527524 [TBL] [Abstract][Full Text] [Related]
34. A comparison of human ultralente- and lente-based twice-daily injection regimens. Tunbridge FK; Newens A; Home PD; Davis SN; Murphy M; Burrin JM; Alberti KG; Jensen I Diabet Med; 1989 Aug; 6(6):496-501. PubMed ID: 2527130 [TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in mainly Asian patients with type 2 diabetes mellitus on metformin and/or a sulphonylurea: A 52-week open-label, randomized phase III trial. Wang W; Nevárez L; Filippova E; Song KH; Tao B; Gu L; Wang F; Li P; Yang J Diabetes Obes Metab; 2019 Feb; 21(2):234-243. PubMed ID: 30129089 [TBL] [Abstract][Full Text] [Related]
36. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Krentz AJ; Bailey CJ Drugs; 2005; 65(3):385-411. PubMed ID: 15669880 [TBL] [Abstract][Full Text] [Related]
37. Metabolic effects of metformin addition to chronic glibenclamide treatment in type 2 diabetes. Marena S; Tagliaferro V; Montegrosso G; Pagano A; Scaglione L; Pagano G Diabete Metab; 1994; 20(1):15-9. PubMed ID: 8056129 [TBL] [Abstract][Full Text] [Related]
38. Appropriate insulin regimes for type 2 diabetes: a multicenter randomized crossover study. Taylor R; Davies R; Fox C; Sampson M; Weaver JU; Wood L Diabetes Care; 2000 Nov; 23(11):1612-8. PubMed ID: 11092282 [TBL] [Abstract][Full Text] [Related]
39. Comparison of lipid profiles and lipoprotein a levels in patients with type 2 diabetes mellitus during oral hypoglycemic or insulin therapy. Habib SS; Aslam M; Naveed AK; Razi MS Saudi Med J; 2006 Feb; 27(2):174-80. PubMed ID: 16501671 [TBL] [Abstract][Full Text] [Related]
40. UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. U.K. Prospective Diabetes Study Group. Diabetes Care; 1998 Jan; 21(1):87-92. PubMed ID: 9538975 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]